Formed in 2019, DELIC has created a psychedelic platform with distinct business divisions focused on psychedelic culture and psychedelic clinics.
DELIC’s divisions include:
- Ketamine Infusion Center (under binding acquisition agreement)
- Two ketamine clinics in Arizona and California
- “Reality Sandwich” – a free public education platform
- “Meet Delic” -a psychedelic wellness summit
- “The Delic” – an e-commerce lifestyle brand.
DELIC has begun to execute its M&A strategy by entering into binding agreements with Ketamine Infusion Center (KIC), with their clinics located in California and Arizona, and of Complex Biotech Discovery Ventures (CBDV) in Vancouver, and more.
Ketamine Infusion Center
On February 5th, 2021 DELIC announced the acquisition of KIC, who over the last 3 years have overseen 4,000 ketamine infusion treatments, while revenues increase to over USD $1.5 million.
“Ketamine was once used mainly as an anesthetic on battlefields and in operating rooms,” reports Harvard Health Publishing (HHP), “Now this medication is gaining ground as a promising treatment for some cases of major depression, which is the leading cause of disability worldwide.
“In the US, recent estimates show 16 million adults had an episode of major depression in the course of a year,” continued HHP, “Suicide rates rose substantially between 1999 and 2016, increasing by more than 30% in 25 states. Because of its rapid action, ketamine could have a role to play in helping to prevent suicide”.
The KIC team has been in the clinic and medical space for over 15 years scaling and operating clinics and hospitals across the United States.
KIC exclusively administers IV Ketamine infusions, which allows them to master the science behind this unique psychedelic therapy.
They utilize a state of art electronic medical record system specifically designed for KIC which allows them to track patient outcomes seamlessly.
With 2 clinics already operating in Arizona and California, DELIC plans to help KIC expand to other states in the near future with a goal of adding 12 to 18 clinics in the next 12 to 18 months.
Closing of the transaction is expected to close Q2, 2021.
Complex Biotech Discovery Ventures
On February 25th, 2021 DELIC announced its acquisition of CBDV (to be renamed DELIC labs), which is a psilocybin and cannabis research lab focused on extraction, analytical testing, and chemical process development.
“The CBDV asset will allow Delic to add scientific-based research and analytics to its product offerings, being as that group received its Section 56 exemption from Health Canada, which allows psilocybin-based research and intellectual property development,” wrote Equity Guru’s Chris Parry on February 26, 2021.
“This is huge,” added Parry, “While others might be toying with product development in private because they don’t want to get, you know, arrested, Delic will be able to get right into SKU generation, advance clinical testing, and slide into medical development which, let’s be honest, will be the first bastion of actual business, much as it was with cannabis back in the day”.
On March 4th 2021 DELIC announced the acquisition of Homestead which is a legacy counterculture distributor of psychedelic media and creator of one of the first self-contained psilocybin mushroom grow kits.
“The deal here is important because the necessity of investor and consumer education cannot be understated when it comes to psychedelics,” writes Equity Guru’s Joseph Morton, “and it’s arguably more important than it was with cannabis. By the time cannabis hit the bigtime, we all basically knew what there was to know about it.
Homestead has sold tens of thousands of mushroom kits globally and is one of the distributors for High Times Holdings.
The Homestead acquisition allows DELIC to increase their product offering on their owned website Reality Sandwich (realitysandwich.com), which most recently hit record average monthly traffic of over 200,000 unique visitors, and over 2.6 million active readers in 2020.
Through Homestead’s extensive intellectual property and heritage brand, DELIC anticipates to revive the “at home EZ Grow experience” targeted at the Reality Sandwich consumer
Product launch is expected in the later half of Q2 2021, and the new mushroom at home grow kit will have a modern interpretation of the company’s history and will include everything a consumer needs to be an at home mycologist – pre-sterilized and as easy as mixing the core ingredients provided.
In addition to the mushroom kit being offered, consumers will also be able to purchase other complementary products to the kit to enhance their experiences and to become better mycologists.
Launch of Meet DELIC Conference:
DELIC will announce the new date for Meet Delic, the premier psychedelic wellness event of the year, in early April.
This will be an opportunity to experience what’s new in psychedelic wellness, connect with the community and expand your horizons in sunny Las Vegas, Nevada.
In this April 7, 2021 Wall Street Reporter live stream, Delic Holdings CEO Matt Stang “lays out the path/milestones that could take DELC to $10 in next 12 months”.
“There’s just this huge opportunity, as we build out this ecosystem,” Stang told Wall Street Reporter, “And as we start really getting to large revenue numbers. People are really interested in vaporization of psychedelics. Guess what, we have the top vaporization specialists in the world.”
“We just got approval from Health Canada to do work on vaporizing psilocybin,” added Stang, “So one of the top search terms in psychedelics is a product that we’re working on developing.”
“Delic expects it can elevate the profile of CBDV through its media properties and connections, which is probably true,” writes Chris Parry, “But almost a negligible side perk compared to having an actual license to handle, extract, test, develop, source and trial the good stuff.”
‘In essence, competitors will be pushed to do some of their business through Delic, because those licenses aren’t tossed around willy nilly,” added Parry.
“What’s in store for the rest of 2021?,” asked Stang rhetorically, “DELIC is focused on expanding its M&A strategy well beyond its early acquisition targets”.
“We look to utilize our mental health platform to assist studies and increase the intellectual properties born from CBDV’s research, (to be renamed DELIC Labs), and our acquisition of Ketamine Infusion Center’s to expand not only across the US, but Canada also, with the goal to expand clinics from 2 current clinics to up to 12 in the next 12 to 18 months.
“As we push forward on this exciting new path and transformation within the psychedelic space. We strive to become a leader in the health and wellness sector and ultimately help people.”
“I am extending a big thank-you to the continued support received from our shareholders,” added Stang, “We’re just getting started.”
– Lukas Kane
Full Disclosure: Delic Holdings is an Equity Guru marketing client and Equity Guru purchased stock in the company